Tech Company Inital Public Offerings
HOOKIPA Pharma IPO
HOOKIPA Pharma was acquired by . The company's stock became public on 4/17/2019.
Transaction Overview
Company Name
Announced On
4/17/2019
Transaction Type
IPO
Amount
$84,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: to advance HB-101 through completion of our ongoing Phase 2 clinical trial; to advance HB-201 and HB-202 into and through completion of Phase 1 clinical trials; to advance HB-301 into and through completion of a Phase 1 clinical trial; for ongoing research and development activities related to next generation programs; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
350 5th Ave. 7240
New York, NY 10118
USA
New York, NY 10118
USA
Phone
Website
Email Address
Overview
Hookipa Pharma Inc. (Nasdaq: HOOK) is a clinical stage company developing products to prevent and cure infectious diseases and cancer. With this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joern Aldag
Chief Financial Officer
Reinhard Kandera
Chief Medical Officer
Igor Matushansky
Chief Scientific Officer
Daniel Pinschewer
VP - Bus. Development
Anders Lilja
VP - Finance
Tony Melckenbeek
VP - R & D
Klaus Orlinger
Browse more venture capital transactions:
Prev: 4/17/2019: Complexa venture capital transaction
Next: 4/18/2019: Sisu Global Health venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs